Stockreport

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio Corporation  (RLYB) 
PDF — Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial — NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clin [Read more]